Comparing the current results to its competitors, Palisade Bio Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Palisade Bio Inc 's competitors' average revenue growth of 12.71 %, achieved in the same quarter.
Palisade Bio Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical sector, specializing in PDE4 inhibitor prodrugs and precision medicine for inflammatory bowel disease (IBD). Its competitors include large pharmaceutical companies with established resources and pipelines in the IBD field, emerging public and private biotechnology firms developing novel IBD therapeutics, and manufacturers of generic and biosimilar products. The company is aware of no other PDE4 inhibitors for folliculitis decalvans (FSCD) in development and only one PDE4 inhibitor for ulcerative colitis (UC) under development in China. Emerging biotechnology companies in this sector compete for funding, talent, and market presence.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Sources:
Palisade Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Palisade Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
